Last checked at 
LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Wednesday it has inked a distribution agreement with UK healthcare technology company MANUS Neurodynamica Ltd.
The agreement provides Cambridge Cognition with the sole rights to market MANUS' Parkinson's Pen, a sensor pen for the diagnosis and monitoring of neuromotor impairments.
After completing some final product enhancements, Cambridge Cognition expects to begin marketing the product, initially for use in academic research, in the fourth quarter of 2016. It will then be marketed for use by healthcare processionals.
"Research and development in Parkinson's disease is a key field for Cambridge Cognition and a hugely important area of research. The addition of the MANUS Parkinson's pen to our neurotechnology portfolio enables us to further leverage our investments in commercial channels and allows us to combine world leading cognitive assessments with cutting-edge physical measures as we continue to advance the understanding, diagnosis and treatment of neurological disorders worldwide," said Chief Executive Officer Steven Powell in a statement.
Financial details of the distribution agreement were not disclosed.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
